Physician profile
Rajeev Agarwal
NPI 1497753750
$1,469.94
in general payments reported to CMS, 2019-2025
15 companies · $340 in 2025
The $340 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.04 · 2020: $52.03 · 2021: $182 · 2022: $192 · 2023: $250 · 2024: $356 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928 · Education: $18.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.83 |
| Education | $18.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $272.34 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $246.68 | 2019-2025 | |
| Welch Allyn | $177.02 | 2019-2021 | |
| Sanofi Pasteur INC. | $153.69 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $123.77 | 2024 | Ycanth |
| Cranial Technologies, INC | $113.89 | 2019-2025 | Doc Band |
| Astrazeneca Pharmaceuticals Lp | $87.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $80.83 | 2025 | Invega Sustenna |
| Seqirus USA INC | $70.57 | 2022-2024 | Flucelvax Quadrivalent, Flucelvax, Fluad |
| Sobi, INC | $37.89 | 2022 | |
| Glaxosmithkline, LLC. | $33.79 | 2019-2024 | Bexsero |
| Abbvie INC. | $21.93 | 2020 | |
| Roche Diagnostics Corporation | $18.55 | 2019 | |
| Aerin Medical INC. | $16.95 | 2020 | |
| Photonicare INC | $14.54 | 2025 | Otosight Middle Ear Scope |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.